President, The International Headache Society.
Intranasal Zolmitriptan for the Treatment of Acute Migraine
Article first published online: 11 SEP 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Special Issue: New Delivery Systems
Volume 53, Issue Supplement S2, pages 62–71, September 2013
How to Cite
Tepper, S. J., Chen, S., Reidenbach, F. and Rapoport, A. M. (2013), Intranasal Zolmitriptan for the Treatment of Acute Migraine. Headache: The Journal of Head and Face Pain, 53: 62–71. doi: 10.1111/head.12181
Conflicts of Interest: Dr. Tepper has received grants/research support (no personal compensation, and not tied to his salary) from ATI, Boston Scientific, GSK, MAP, Merck, NuPathe, OptiNose, Valkee, and Zogenix. He has received personal compensation (<$10,000 per company) from serving as a consultant from Allergan, ATI, Impax, MAP, Merck, Nautilus, NuPathe, and Zogenix; on speakers bureaus for Allergan, ATI, Impax, Nautilus, and Zogenix; and on advisory boards for Allergan, ATI, Merck, MAP, Nautilus, NuPathe, Pfizer, USWorldMeds, and Zogenix. He has received stock options from ATI and royalties from University of Mississippi Press, Peoples Publishing House of Peking, and Springer. His spouse has served on an advisory board for Zogenix (<$10,000). Dr. Chen is an employee of Impax Laboratories and owns stock in Impax Laboratories. Ms. Reidenbach has received medical writing fees from Impax Laboratories and MAP Pharmaceuticals. Her spouse has been a consultant for Amgen. Dr. Rapoport has served on speakers bureaus for Allergan, Impax, and Nautilus Neurosciences, and on advisory boards for Impax, NautilusNeurosciences, NuPathe, Winston, and Zogenix.
Financial Support: This paper was supported by Impax Laboratories, Inc., but the physician authors were not compensated.
- Issue published online: 11 SEP 2013
- Article first published online: 11 SEP 2013
- Manuscript Accepted: 12 MAY 2013
- Impax Laboratories, Inc.
- zolmitriptan nasal spray;
- migraine treatment;
- onset of action;
- serotonin 5-HT1B/1D receptor agonist
To review the pharmacokinetics, efficacy, tolerability, and patient acceptance of zolmitriptan nasal spray (NS).
Gastroparesis may delay or diminish the absorption of oral triptans, and nausea or vomiting may do the same and/or make it difficult to take a tablet. Some migraineurs require or prefer faster relief than oral medications provide. Injectable triptans provide the fastest drug delivery into the bloodstream, but many patients are reluctant to use them. Nasal sprays may address some of the problems with tablets and injectables while still providing rapid absorption of drug.
Significant levels of zolmitriptan NS are detectable in plasma within 2-5 minutes, and the rapid absorption is due to early uptake through the nasal mucosa. In 2 randomized trials, users of zolmitriptan NS were significantly more likely than placebo recipients to be pain-free at 15 minutes post-dose, the first time point measured, and about half of patients had sustained response at 24 hours. Studies in which patients could treat a migraine of any severity have documented significant headache response or relief with zolmitriptan NS at 10 minutes. In one trial, the rate of total symptom relief was significantly better with the NS than with placebo from 30 minutes post-dose. The most common side effect of zolmitriptan NS is unusual taste. Patient satisfaction studies indicate that zolmitriptan NS is appreciated for its speed of onset, ease of use, reliability, and overall efficacy.
Zolmitriptan NS provides onset of headache relief within 10 minutes for some patients and quickly abolishes some of the major migraine symptoms. Good candidates are migraineurs whose episodes rapidly escalate to moderate-to-severe pain and those who have morning migraine, have a quick time to vomiting, or have failed oral triptans.